Margaret A. Foley

643 total citations
14 papers, 402 citations indexed

About

Margaret A. Foley is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Margaret A. Foley has authored 14 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Margaret A. Foley's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Research Studies (4 papers). Margaret A. Foley is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Research Studies (4 papers). Margaret A. Foley collaborates with scholars based in United States, Canada and United Kingdom. Margaret A. Foley's co-authors include Jiuzhou Wang, Julie D. Horan, Karen Kelly, Mary O’Brien, Wilfried Eberhardt, Frances A. Shepherd, Nasser K. Altorki, Piotr Serwatowski, Joo-Hang Kim and Lucio Crinò and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Margaret A. Foley

13 papers receiving 394 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Margaret A. Foley United States 6 365 245 66 40 40 14 402
Julie D. Horan United States 6 339 0.9× 247 1.0× 63 1.0× 38 0.9× 25 0.6× 11 391
Myriam Taibi United States 3 325 0.9× 373 1.5× 95 1.4× 40 1.0× 33 0.8× 5 470
Yoshiro Nakahara Japan 12 255 0.7× 282 1.2× 54 0.8× 55 1.4× 18 0.5× 42 414
G. Groth Germany 5 279 0.8× 264 1.1× 50 0.8× 102 2.5× 73 1.8× 7 375
You Lu China 9 298 0.8× 251 1.0× 46 0.7× 59 1.5× 12 0.3× 22 338
L. Paz-Ares Spain 9 215 0.6× 291 1.2× 40 0.6× 97 2.4× 23 0.6× 51 374
Wayne Saville United States 4 323 0.9× 347 1.4× 54 0.8× 57 1.4× 14 0.3× 8 446
Xun Shi China 10 253 0.7× 231 0.9× 109 1.7× 72 1.8× 13 0.3× 27 361
J. McCoy United States 9 350 1.0× 312 1.3× 74 1.1× 100 2.5× 17 0.4× 19 421
H. Akamatsu Japan 4 279 0.8× 211 0.9× 89 1.3× 68 1.7× 12 0.3× 10 314

Countries citing papers authored by Margaret A. Foley

Since Specialization
Citations

This map shows the geographic impact of Margaret A. Foley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret A. Foley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret A. Foley more than expected).

Fields of papers citing papers by Margaret A. Foley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret A. Foley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret A. Foley. The network helps show where Margaret A. Foley may publish in the future.

Co-authorship network of co-authors of Margaret A. Foley

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret A. Foley. A scholar is included among the top collaborators of Margaret A. Foley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret A. Foley. Margaret A. Foley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Ilie, G., Ricardo Rendon, Ross Mason, et al.. (2025). Evaluating the cost-effectiveness of the Prostate Cancer Patient Empowerment Program. Canadian Urological Association Journal. 19(12). 410–419.
2.
Jakacki, Regina I., Margaret A. Foley, Julie D. Horan, et al.. (2016). Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. Journal of Neuro-Oncology. 129(1). 131–138. 20 indexed citations
3.
4.
Yu, Helena A., Geoffrey R. Oxnard, Alexander I. Spira, et al.. (2015). Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.. Journal of Clinical Oncology. 33(15_suppl). 8083–8083. 12 indexed citations
5.
Shepherd, Frances A., Wilfried Eberhardt, Nasser K. Altorki, et al.. (2015). Common and rare EGFR mutations (EGFRm) in the RADIANT trial: Final follow-up with 5 year data.. Journal of Clinical Oncology. 33(15_suppl). 7539–7539. 3 indexed citations
6.
Joshua, Anthony M., Neal D. Shore, Fred Saad, et al.. (2015). Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America. The Prostate. 75(8). 836–844. 16 indexed citations
7.
Kelly, Karen, Nasser K. Altorki, Wilfried Eberhardt, et al.. (2015). Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 33(34). 4007–4014. 283 indexed citations
8.
O’Brien, Mary, Wilfried Eberhardt, Nasser K. Altorki, et al.. (2014). Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.. Journal of Clinical Oncology. 32(15_suppl). 7535–7535. 2 indexed citations
9.
10.
Shepherd, Frances A., Nasser K. Altorki, Wilfried Eberhardt, et al.. (2014). Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial.. Journal of Clinical Oncology. 32(15_suppl). 7513–7513. 16 indexed citations
11.
Joshua, Anthony M., Neal D. Shore, Fred Saad, et al.. (2014). Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. Journal of Clinical Oncology. 32(15_suppl). 5051–5051. 2 indexed citations
12.
Altorki, Nasser K., Mary O’Brien, Wilfried Eberhardt, et al.. (2014). Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results. International Journal of Radiation Oncology*Biology*Physics. 90(5). S2–S3. 2 indexed citations
13.
Shepherd, Frances A., Nasser K. Altorki, Wilfried Eberhardt, et al.. (2014). Prognostic and Predictive Roles of Egfr Copy Number and Kras Mutation Status from the Radiant Trial of Adjuvant Erlotinib (E) Versus Placebo (P). Annals of Oncology. 25. iv409–iv409. 2 indexed citations
14.
Geary, Michael, et al.. (1995). Recurrent ovarian carcinoma: diagnosis and second-line therapy.. PubMed. 88(2). 68–70. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie D. Horan Breakdown of academic impact, for papers by Myriam Taibi Breakdown of academic impact, for papers by Yoshiro Nakahara Breakdown of academic impact, for papers by G. Groth Breakdown of academic impact, for papers by You Lu Breakdown of academic impact, for papers by L. Paz-Ares Breakdown of academic impact, for papers by Wayne Saville Breakdown of academic impact, for papers by Xun Shi Breakdown of academic impact, for papers by J. McCoy Breakdown of academic impact, for papers by H. Akamatsu
Rankless by CCL
2026